Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we rep...

Full description

Saved in:
Bibliographic Details
Published inCell transplantation Vol. 30; p. 963689721996649
Main Authors Wang, Tianyi, Feng, Mingxuan, Luo, Chengjuan, Wan, Xinyu, Pan, Ci, Tang, Jingyan, Xue, Feng, Yin, Minzhi, Lu, Dongqing, Xia, Qiang, Li, Benshang, Chen, Jing
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 2021
Sage Publications Ltd
SAGE Publishing
Subjects
Antigens
Autografts
Biliary atresia
Burkitt's lymphoma
CD19 antigen
Chemotherapy
Cyclophosphamide
Cytokines
Epstein-Barr virus
Fludarabine
Immunosuppressive agents
Immunotherapy
Liver transplantation
Liver transplants
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Monoclonal antibodies
Neonates
Neurotoxicity
Original
p53 Protein
Paraffin
Patients
Pediatrics
Posttransplant lymphoproliferative disorders
Remission
Stem cell transplantation
Transplants & implants
Tumors
PTLD
CAR T-cells
CD19
Burkitt lymphoma
Online AccessGet full text

Cover

Abstract In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD. Clinical trial number: ChiCTR2000032211.
AbstractList In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 10 6 /kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD. Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/- intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD.Clinical trial number: ChiCTR2000032211.In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/- intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD.Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD.Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/- intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 10 /kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD.Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 10 6 /kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD. Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 106/kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD. Clinical trial number: ChiCTR2000032211.
In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we report the successful treatment of refractory BL-PTLD with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. A male patient was diagnosed with BL-PTLD, with an increasing Epstein-Barr virus (EBV) viral load, at 21 months after undergoing living liver transplantation from his mother due to neonatal biliary atresia. After 10 cycles rituximab +/− intensive chemotherapy and surgical tumor resection, the tumors significantly advanced. Next-generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded tumor tissue, revealing one mutation in exon 5, TP53: p.A159 V, which may be associated with chemo-resistance. Thus, treatment was started with autologous anti-CD19 CAR T-cell therapy. We administered 9.0 × 10 6 /kg autologous anti-CD19 CAR T-cells, after conditioning with cyclophosphamide and fludarabine. Unexpectedly, the patient experienced only mild (Grade II) cytokine release syndrome (CRS) without neurotoxicity. Finally, he went into complete remission (CR), and has achieved 16-month event-free survival to date. In addition, liver function has remained stably within the normal range without any immunosuppressive therapy. The literature includes only five previously reported BL cases treated with CAR T-cell therapy. In conclusion, the present case suggests that autologous anti-CD19 CAR T-cell therapy may represent a new therapeutic option for some cases of refractory BL-PTLD. Clinical trial number: ChiCTR2000032211.
Author Tang, Jingyan
Feng, Mingxuan
Xia, Qiang
Wan, Xinyu
Xue, Feng
Lu, Dongqing
Wang, Tianyi
Pan, Ci
Li, Benshang
Luo, Chengjuan
Yin, Minzhi
Chen, Jing
AuthorAffiliation Both the authors contributed equally as co-first author
3 Department of Pathology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Department of Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
AuthorAffiliation_xml – name: 1 Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
– name: Both the authors contributed equally as co-first author
– name: 2 Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
– name: 3 Department of Pathology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
– name: 4 Department of Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Author_xml – sequence: 1
  givenname: Tianyi
  surname: Wang
  fullname: Wang, Tianyi
– sequence: 2
  givenname: Mingxuan
  surname: Feng
  fullname: Feng, Mingxuan
– sequence: 3
  givenname: Chengjuan
  surname: Luo
  fullname: Luo, Chengjuan
– sequence: 4
  givenname: Xinyu
  surname: Wan
  fullname: Wan, Xinyu
– sequence: 5
  givenname: Ci
  surname: Pan
  fullname: Pan, Ci
– sequence: 6
  givenname: Jingyan
  surname: Tang
  fullname: Tang, Jingyan
– sequence: 7
  givenname: Feng
  surname: Xue
  fullname: Xue, Feng
– sequence: 8
  givenname: Minzhi
  surname: Yin
  fullname: Yin, Minzhi
– sequence: 9
  givenname: Dongqing
  surname: Lu
  fullname: Lu, Dongqing
– sequence: 10
  givenname: Qiang
  surname: Xia
  fullname: Xia, Qiang
  email: xiaqiang@shsmu.edu.cn
– sequence: 11
  givenname: Benshang
  surname: Li
  fullname: Li, Benshang
– sequence: 12
  givenname: Jing
  orcidid: 0000-0003-2895-700X
  surname: Chen
  fullname: Chen, Jing
  email: chenjing@scmc.com.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33631963$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhUeoiKaFPStkiQ2bAT_mYW-QSsqjUiQqCGvL47lOHGbs1PZUyi_h7-KQFmgk2NiS7zmfju-9Z8WJ8w6K4jnBrwlp2zdYNKzhoqVEiKapxKNiRuq6LhkX9KSY7cvlvn5anMW4wRi3jNZPilPGGkZycVb8-DppDTGaaUDLACqN4BLyBl1Db1UKVqMvYILSyYcdejeF7zYltNiN27UfFbpeLi6RMgkCWtjbfC6DcnE7KJdUst6hKVq3Qhcu2XJ-SQSar-0Ie-r-aQUu0zVsMxwtyzkMOcQagtrunhaPjRoiPLu7z4tvH94v55_KxeePV_OLRalrylNJKwEcU-g10T0HpkDVPcVdzzntSGs6Tjm0rOuAc9PVNTFQQ6uVUB1vhGnZeXF14PZebeQ22FGFnfTKyl8PPqykCsnqASTuGaXK9E0NvOqI6aDrVU9rodq-wbXIrLcH1nbqxhwpdzKo4QH0YcXZtVz5W9kK0lakyoBXd4DgbyaISY426twV5cBPUebfVgwzXLEsfXkk3fgpuNwqSRvCKBcV5Vn14u9Ev6Pczz8LmoNABx9jACO1PUwuB7SDJFjuF00eL1o24iPjPfs_lvJgiWoFf-L-U_8TKojj-Q
CitedBy_id crossref_primary_10_1097_MPH_0000000000002804
crossref_primary_10_3389_fonc_2022_932254
crossref_primary_10_1038_s41409_022_01907_z
crossref_primary_10_1016_j_retram_2021_103304
crossref_primary_10_1111_bjh_18763
crossref_primary_10_1080_21645515_2023_2216116
crossref_primary_10_1097_TXD_0000000000001584
crossref_primary_10_1080_10428194_2022_2076853
crossref_primary_10_1182_blood_2024024765
crossref_primary_10_1016_j_semnephrol_2023_151348
crossref_primary_10_3390_jpm13111595
crossref_primary_10_3389_fonc_2021_726134
crossref_primary_10_1097_HS9_0000000000000733
crossref_primary_10_1016_j_msard_2023_104590
crossref_primary_10_3389_fimmu_2022_879983
crossref_primary_10_1097_MNH_0000000000000737
crossref_primary_10_3390_children8080661
crossref_primary_10_1007_s40278_022_28876_1
crossref_primary_10_1016_j_scib_2025_01_002
crossref_primary_10_1016_j_semnephrol_2024_151501
crossref_primary_10_1111_tri_14115
crossref_primary_10_3390_medsci11040067
crossref_primary_10_1016_j_semnephrol_2024_151498
crossref_primary_10_3389_fimmu_2023_1285406
Cites_doi 10.1172/JCI121127
10.1097/00007890-200104270-00012
10.1172/jci.insight.130195
10.1007/s00432-020-03198-7
10.1136/archdischild-2015-310023
10.1046/j.1365-2141.2003.04134.x
10.1002/hep.25820
10.1046/j.1600-6143.2003.00325.x
10.1038/s41591-018-0036-4
10.1182/blood-2017-06-793141
10.1182/blood-2006-12-063008
10.1111/j.1399-3046.2012.01713.x
10.1056/NEJMoa1407222
10.1126/scitranslmed.3002842
10.1038/s41409-018-0235-0
10.1016/j.bbmt.2018.12.758
10.1182/blood-2011-01-293050
10.1002/cncr.27482
10.1002/pbc.27873
10.1200/JCO.2009.25.4961
10.3389/fonc.2019.00767
10.3389/fonc.2019.00146
10.1001/jama.2011.1592
10.1182/blood-2005-01-0377
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021 2021 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021 2021 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7T5
7X7
7XB
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
H94
K9.
M0S
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1177/0963689721996649
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central China
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Anatomy & Physiology
Biology
EISSN 1555-3892
ExternalDocumentID oai_doaj_org_article_0d322afd65e84b1fbebdad259a7d6059
PMC7917414
33631963
10_1177_0963689721996649
10.1177_0963689721996649
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Shanghai Collaborative Innovation Center for Translational Medicine
  grantid: TM201928
– fundername: ;
  grantid: TM201928
GroupedDBID ---
0R~
29B
4.4
54M
5GY
7X7
8FI
8FJ
AASGM
ABJIS
ABQXT
ABUWG
ABVFX
ACARO
ACROE
ADBBV
ADOGD
AENEX
AEWDL
AFCOW
AFKRA
AFKRG
AFRWT
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AUTPY
AYAKG
BAWUL
BCNDV
BDDNI
BENPR
BPHCQ
BSEHC
BVXVI
CCPQU
CS3
DC.
DU5
EBS
EMOBN
F5P
FDB
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
HZ~
J8X
K.F
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
Q1R
R9-
ROL
RPM
SAUOL
SCDPB
SCNPE
SFC
UKHRP
AAYXX
ACHEB
CITATION
--K
0VX
1B1
31X
53G
AAEDT
AAGGD
AALRI
AAPEO
AAQGT
AAQXH
AAQXK
AATBZ
AAXUO
ABDWY
ABQKF
ABWVN
ABYTW
ACFMA
ACGBL
ACGZU
ACLHI
ACRPL
ACSIQ
ADEIA
ADMUD
ADNMO
ADTBJ
ADUKL
AEWHI
AFDWT
AFYCX
AJEFB
AJMMQ
APTNG
CBRKF
CORYS
CQQTX
DIK
DV7
EJD
FEDTE
FGOYB
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
HVGLF
IHE
M41
M4V
NPM
NQ-
R2-
RPZ
SFK
SFT
SGV
SPP
UHS
3V.
7T5
7XB
8FD
8FK
AZQEC
DWQXO
FR3
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c528t-249e802edc1cd8e3aea5d20bd882b17fb828e73bbe88fb551fe5e7ca9ab869f73
IEDL.DBID 7X7
ISSN 0963-6897
1555-3892
IngestDate Wed Aug 27 01:21:59 EDT 2025
Thu Aug 21 14:06:50 EDT 2025
Fri Jul 11 06:35:35 EDT 2025
Mon Jun 30 12:14:56 EDT 2025
Thu Jan 02 22:56:07 EST 2025
Tue Jul 01 05:27:40 EDT 2025
Thu Apr 24 23:05:34 EDT 2025
Tue Jun 17 22:30:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords PTLD
CAR T-cells
CD19
Burkitt lymphoma
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-249e802edc1cd8e3aea5d20bd882b17fb828e73bbe88fb551fe5e7ca9ab869f73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0003-2895-700X
OpenAccessLink https://www.proquest.com/docview/2613289428?pq-origsite=%requestingapplication%
PMID 33631963
PQID 2613289428
PQPubID 4450831
ParticipantIDs doaj_primary_oai_doaj_org_article_0d322afd65e84b1fbebdad259a7d6059
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7917414
proquest_miscellaneous_2494303043
proquest_journals_2613289428
pubmed_primary_33631963
crossref_citationtrail_10_1177_0963689721996649
crossref_primary_10_1177_0963689721996649
sage_journals_10_1177_0963689721996649
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: Thousand Oaks
– name: Sage CA: Los Angeles, CA
PublicationTitle Cell transplantation
PublicationTitleAlternate Cell Transplant
PublicationYear 2021
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Wang, Lo, Chen, Cheung, Yang, Chen, Ng, Yu, Ming, Zhang, Ho 2012; 56
Opelz, Dohler 2004; 4
Lee, Santomasso, Locke, Ghobadi, Turtle, Brudno, Maus, Park, Mead, Pavletic, Go 2019; 25
Choquet, Leblond, Herbrecht, Socie, Stoppa, Vandenberghe, Fischer, Morschhauser, Salles, Feremans, Vilmer 2006; 107
Kalos, Levine, Porter, Katz, Grupp, Bagg, June 2011; 3
Shah, Maatman, Hari, Johnson 2019; 9
Cao, Lu, Sun, Jin, Cheng, He, Wang, Yuan, Lyu, Zhao 2019; 9
Orjuela, Gross, Cheung, Alobeid, Morris, Cairo 2003; 9
Cairo, Sposto, Perkins, Meadows, Hoover-Regan, Anderson, Siegel, Lones, Tedeschi-Blok, Kadin, Kjeldsberg 2003; 120
Avigdor, Shouval, Jacoby, Davidson, Shimoni, Besser, Nagler 2018; 53
Li, Zhang, Zhang, Chen, Lou, Chen, Kang, Xu, Li, Tan, Sun 2019; 5
Hay, Hanafi, Li, Gust, Liles, Wurfel, Lopez, Chen, Chung, Harju-Baker, Cherian 2017; 130
Evens, David, Helenowski, Nelson, Kaufman, Kircher, Gimelfarb, Hattersley, Mauro, Jovanovic, Chadburn 2010; 28
Maude, Frey, Shaw, Aplenc, Barrett, Bunin, Chew, Gonzalez, Zheng, Lacey, Mahnke 2014; 371
Tsai, Hardy, Tomaszewski, Kotloff, Oltoff, Somer, Schuster, Porter, Montone, Stadtmauer 2001; 71
Campo, Swerdlow, Harris, Pileri, Stein, Jaffe 2011; 117
Weiner, Weintraub, Wistinghausen, Tomaino, Arnon, Kerkar, Miloh 2012; 16
Kohli, Cortes, Heaton, Dhawan 2018; 103
Haque, Wilkie, Jones, Higgins, Urquhart, Wingate, Burns, McAulay, Turner, Bellamy, Amlot 2007; 110
Engels, Pfeiffer, Fraumeni, Kasiske, Israni, Snyder, Wolfe, Goodrich, Bayakly, Clarke, Copeland 2011; 306
Zimmermann, Reinke, Neuhaus, Lehmkuhl, Oertel, Atta, Planker, Gartner, Lenze, Anagnostopoulos, Riess 2012; 118
Norelli, Camisa, Barbiera, Falcone, Purevdorj, Genua, Sanvito, Ponzoni, Doglioni, Cristofori, Traversari 2018; 24
Du, Zhang 2020; 146
Rigaud, Auperin, Jourdain, Haouy, Couec, Aladjidi, Gandemer, Lambliotte, Plat, Landman-Parker, Michon 2019; 66
Prockop, Doubrovina, Suser, Heller, Barker, Dahi, Perales, Papadopoulos, Sauter, Castro-Malaspina, Boulad 2020; 130
Krishnamoorthy, Ghobadi, Delos Santos, Schilling, Malone, Murad, Bartlett, Alhamad 2020
bibr1-0963689721996649
bibr19-0963689721996649
Krishnamoorthy S (bibr16-0963689721996649) 2020
bibr23-0963689721996649
bibr15-0963689721996649
bibr22-0963689721996649
bibr6-0963689721996649
bibr7-0963689721996649
bibr2-0963689721996649
bibr24-0963689721996649
bibr21-0963689721996649
bibr17-0963689721996649
bibr25-0963689721996649
bibr20-0963689721996649
Orjuela M (bibr12-0963689721996649) 2003; 9
bibr4-0963689721996649
bibr11-0963689721996649
bibr26-0963689721996649
bibr13-0963689721996649
bibr8-0963689721996649
bibr18-0963689721996649
bibr5-0963689721996649
bibr10-0963689721996649
Zimmermann H (bibr3-0963689721996649) 2012; 118
bibr9-0963689721996649
bibr14-0963689721996649
References_xml – volume: 71
  start-page: 1076
  issue: 8
  year: 2001
  end-page: 1088
  article-title: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients
  publication-title: Transplantation
– volume: 16
  start-page: 458
  issue: 5
  year: 2012
  end-page: 464
  article-title: Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease
  publication-title: Pediatr Transplant
– volume: 5
  start-page: e130195
  issue: 17
  year: 2019
  article-title: Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma
  publication-title: JCI Insight
– volume: 56
  start-page: 1557
  issue: 4
  year: 2012
  end-page: 1566
  article-title: Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver
  publication-title: Hepatology
– volume: 117
  start-page: 5019
  issue: 19
  year: 2011
  end-page: 5032
  article-title: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
  publication-title: Blood
– volume: 9
  start-page: 767
  year: 2019
  article-title: Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell non-hodgkin lymphoma
  publication-title: Front Oncol
– volume: 107
  start-page: 3053
  issue: 8
  year: 2006
  end-page: 3057
  article-title: Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
  publication-title: Blood
– volume: 371
  start-page: 1507
  issue: 16
  year: 2014
  end-page: 1517
  article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia
  publication-title: N Engl J Med
– volume: 110
  start-page: 1123
  issue: 4
  year: 2007
  end-page: 1131
  article-title: Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
  publication-title: Blood
– volume: 146
  start-page: 1575
  issue: 6
  year: 2020
  end-page: 1582
  article-title: Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
  publication-title: J Cancer Res Clin Oncol
– volume: 4
  start-page: 222
  issue: 2
  year: 2004
  end-page: 230
  article-title: Lymphomas after solid organ transplantation: a collaborative transplant study report
  publication-title: Am J Transplant
– volume: 28
  start-page: 1038
  issue: 6
  year: 2010
  end-page: 1046
  article-title: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
  publication-title: J Clin Oncol
– volume: 25
  start-page: 625
  issue: 4
  year: 2019
  end-page: 638
  article-title: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
  publication-title: Biol Blood Marrow Transplant
– volume: 9
  start-page: 3945S
  issue: 10 Pt 2
  year: 2003
  end-page: 3952S
  article-title: A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation
  publication-title: Clin Cancer Res
– volume: 306
  start-page: 1891
  issue: 17
  year: 2011
  end-page: 1901
  article-title: Spectrum of cancer risk among US solid organ transplant recipients
  publication-title: JAMA
– volume: 118
  start-page: 4715
  issue: 19
  year: 2012
  end-page: 4724
  article-title: Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients
  publication-title: Cancer
– volume: 130
  start-page: 733
  issue: 2
  year: 2020
  end-page: 747
  article-title: Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
  publication-title: J Clin Invest
– volume: 53
  start-page: 1583
  issue: 12
  year: 2018
  end-page: 1585
  article-title: CAR T cells induce a complete response in refractory Burkitt Lymphoma
  publication-title: Bone Marrow Transplant
– volume: 120
  start-page: 660
  issue: 4
  year: 2003
  end-page: 670
  article-title: Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience
  publication-title: Br J Haematol
– volume: 130
  start-page: 2295
  issue: 21
  year: 2017
  end-page: 2306
  article-title: Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
  publication-title: Blood
– volume: 66
  start-page: e27873
  issue: 9
  year: 2019
  article-title: Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study
  publication-title: Pediatr Blood Cancer
– year: 2020
  article-title: CAR-T therapy in solid organ transplant recipients with treatment refractory post transplant lymphoproliferative disorder
  publication-title: Am J Transplant
– volume: 24
  start-page: 739
  issue: 6
  year: 2018
  end-page: 748
  article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
  publication-title: Nat Med
– volume: 9
  start-page: 146
  year: 2019
  article-title: Multi targeted CAR-T cell therapies for B-cell malignancies
  publication-title: Front Oncol
– volume: 3
  start-page: 95ra73
  issue: 95
  year: 2011
  article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
  publication-title: Sci Transl Med
– volume: 103
  start-page: 192
  issue: 2
  year: 2018
  end-page: 198
  article-title: Liver transplantation in children: state of the art and future perspectives
  publication-title: Arch Dis Child
– ident: bibr14-0963689721996649
  doi: 10.1172/JCI121127
– ident: bibr4-0963689721996649
  doi: 10.1097/00007890-200104270-00012
– ident: bibr8-0963689721996649
  doi: 10.1172/jci.insight.130195
– ident: bibr22-0963689721996649
  doi: 10.1007/s00432-020-03198-7
– ident: bibr24-0963689721996649
  doi: 10.1136/archdischild-2015-310023
– ident: bibr13-0963689721996649
  doi: 10.1046/j.1365-2141.2003.04134.x
– ident: bibr26-0963689721996649
  doi: 10.1002/hep.25820
– ident: bibr2-0963689721996649
  doi: 10.1046/j.1600-6143.2003.00325.x
– ident: bibr18-0963689721996649
  doi: 10.1038/s41591-018-0036-4
– volume: 9
  start-page: 3945S
  issue: 10
  year: 2003
  ident: bibr12-0963689721996649
  publication-title: Clin Cancer Res
– ident: bibr19-0963689721996649
  doi: 10.1182/blood-2017-06-793141
– ident: bibr5-0963689721996649
  doi: 10.1182/blood-2006-12-063008
– ident: bibr25-0963689721996649
  doi: 10.1111/j.1399-3046.2012.01713.x
– ident: bibr21-0963689721996649
  doi: 10.1056/NEJMoa1407222
– ident: bibr20-0963689721996649
  doi: 10.1126/scitranslmed.3002842
– ident: bibr17-0963689721996649
  doi: 10.1038/s41409-018-0235-0
– ident: bibr9-0963689721996649
  doi: 10.1016/j.bbmt.2018.12.758
– ident: bibr6-0963689721996649
  doi: 10.1182/blood-2011-01-293050
– volume: 118
  start-page: 4715
  issue: 19
  year: 2012
  ident: bibr3-0963689721996649
  publication-title: Cancer
  doi: 10.1002/cncr.27482
– ident: bibr23-0963689721996649
  doi: 10.1002/pbc.27873
– ident: bibr11-0963689721996649
  doi: 10.1200/JCO.2009.25.4961
– ident: bibr7-0963689721996649
  doi: 10.3389/fonc.2019.00767
– ident: bibr15-0963689721996649
  doi: 10.3389/fonc.2019.00146
– ident: bibr1-0963689721996649
  doi: 10.1001/jama.2011.1592
– year: 2020
  ident: bibr16-0963689721996649
  publication-title: Am J Transplant
– ident: bibr10-0963689721996649
  doi: 10.1182/blood-2005-01-0377
SSID ssj0007325
Score 2.4248219
Snippet In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 963689721996649
SubjectTerms Antigens
Autografts
Biliary atresia
Burkitt's lymphoma
CD19 antigen
Chemotherapy
Cyclophosphamide
Cytokines
Epstein-Barr virus
Fludarabine
Immunosuppressive agents
Immunotherapy
Liver transplantation
Liver transplants
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Monoclonal antibodies
Neonates
Neurotoxicity
Original
p53 Protein
Paraffin
Patients
Pediatrics
Posttransplant lymphoproliferative disorders
Remission
Stem cell transplantation
Transplants & implants
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB2hSkhwQLTlI1CQkVAlDtEmcex4j7tbqgqtEIKt1FtkxzZddZugJTnsL-Hvdux8dJcWuHCLEieaeCb2G_vlDcB7jqBYaFmEwhSYoHCnAZlw5gZDqo2OJFeeIPuZn52nny7YxVapL8cJa-WB244bRRpDTlrNmRGpiq0ySkuNoF1mGqG4_3UP57w-merG4Iwm7HZTcoQ4nXLhhGocvHe6mVuTkNfqvw9g3uVJbpG9_Pxz-hSedMCRTFqD9-GBKQ_gcFJi0ny9IcfEUzn9GvkBPJz2R4-39AYP4de3xtdHtM2KLHqGOaksGQp2kK_Grn0Jng2ZNuurZV2T-QY9Xl1L8mUxPyG-qDiZOzoHaZXRV7L9fakkjkT_nUzKehnOTuIxmV0u_YaQP4WRik93LJoK7wxnZoVGtJoGz-D89ONidhZ2lRnCgiWiDjFnMyJKsGfiQgtDpZFMJ5HSiNdVnFmFeZzJqFJGCKsQlFnDTFbIsVSCj21Gn8NeWZXmJZBYxoYxv9vJU2XR1VKrVBVKCcyMijiAUe-qvOhky131jFUe90rlvzk3gA_DHT9ayY6_tJ067w_tnNi2P4EhmHchmP8rBAM46mMn70aAnzlmphSTWXyHAN4Nl_HbdRsysjRVg21SJ35Po5QG8KINtcESSrkfHQPIdoJwx9TdK-Xy0uuDZ5iCp3EawLEL11uT_tQJr_5HJ7yGR4mj-_jVqSPYq9eNeYN4rVZv_ad5Azj4PR4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdGJyR4QLDxERjISGgSD6FJnDjuE2o7qglVCI1O7C2yY3uraBNUkof-Jfy73DkfWxkg3iLHcS722bnz_fw7Qt5wMIqFlrkvTA4OCkcOyIgnuBgybXQguXIA2U_89Dz-eJFc7JGiOwvT9uCPdwirAoncYo2zG3ejh22QcQh2N-MCiWfQXI9H7-tqnTW73V1SDSzB8HS9xsh2jnjIrd-dbrtD9qOUJ9GA7I9nZ18X_dqdMpemFdv38QXXgc1b79z5kTm-_z8ZqbexljcAY-4fNntIHrTGJx032vKI7JnigByOC3C811t6TB0c1O2zH5C7k-7q_g3OwkPy80vtcixCT9FFh1KnpaV90g96ZuzGpfHZ0km9-basKjrfgtaUa0k_L-Yn1CUmp3OEhNCGXX0lmyNQBUUg_iUdF9XSn56EIzq9WrqgkisCbYfWEYlTwpP-1KxAiIYX4TE5n31YTE_9NruDnyeRqHzw-4wIIuiZMNfCMGlkoqNAabD5VZhaBb6gSZlSRgirwLCzJjFpLkdSCT6yKXtCBkVZmGeEhjI0SeIipjxWNpJWahWrXCkB3lUeemTYDVWWt9TnmIFjlYUd2_lvg-uRt_0T3xvaj3_UneDo9_WQsNsVlJvLrJ3_WaBh5ZRW88SIWIVWGaWlBt9Tpho8SmjkqNOdrJsDGXi3DBxi-AaPvO5vw_zHoI4sTFlDnRgJ9FkQM488bVStl4Qx7lZYj6Q7Srgj6u6dYnnlOMZTcOPjMPbIMarrtUh_64Tn_1vxBbkXISzI7WIdkUG1qc1LsOsq9aqdjL8ATtpIzg
  priority: 102
  providerName: SAGE Publications
Title Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
URI https://journals.sagepub.com/doi/full/10.1177/0963689721996649
https://www.ncbi.nlm.nih.gov/pubmed/33631963
https://www.proquest.com/docview/2613289428
https://www.proquest.com/docview/2494303043
https://pubmed.ncbi.nlm.nih.gov/PMC7917414
https://doaj.org/article/0d322afd65e84b1fbebdad259a7d6059
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEF7ahEJ7KG3Sh9LUbKEEehC2Xqv1qdhOTCgmBNehvold7W5i6kiJIx38S_p3O7N62O4jJ4nVSgya2dHMzqdvCPnMICjmSqQu1ykkKAw5IH0WoTMMlFY9waQFyF6w86vw2zya1xtuDzWssvGJ1lGrPMU98i5E-gEkBxAtf727d7FrFFZX6xYaT8k-UpehVcfzNuEC67VNVyFKD1zG-_GmTNnFMRzyEYXLkElz67Nk2fv_FXL-jZzcgn_ZL9L4FXlZh5J0UOn-NXmiswNyOMggjb5d0xNqwZ121_yAPBs2Zy-2GAgPya_vpe2YaMolnTWYc5ob2rbwoFNtVrYpz5oOy9XPRVHQyRpsIL8V9HI2OaW2zTidIMCDVlzpS1H90JRRhNVf00FWLNzRqdeno5uFLRHZIbBdeDrianK40x3pJQhRsRy8IVfjs9no3K17Nbhp5PPChSxO854Pb8ZLFdeB0CJSfk8qiOClFxsJmZ2OAyk150ZCmGZ0pONU9IXkrG_i4C3Zy_JMvyfUE56OIlv_ZKE0vjBCyVCmUnLQfuo5pNuoKklrInPsp7FMvIa7_A_lOuRLe8ddReLxyNwhar-dh_TbdiBfXSf1ak56CvygMIpFmofSM1JLJRRkkiJWkB_CQ44b20lqn_CQbCzYIZ_ay7CasUQjMp2XMCdEOvygFwYOeVeZWitJEDDrLx0S7xjhjqi7V7LFjWUMjyEpD73QISdorhuR_vcSjh6X_wN57iO0x-5EHZO9YlXqjxCbFbJjF2CH7A_G0x8zOA7PLi6nHbvT8RtK5Dmc
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4aQwh4QLBxCQwwEkziIWqujvuAUC9MGysTgk7qW2bH9lbRJaNLhfpL-Bf8Ro6dJm257G1vleNYVn18fD6fL98BeE0xKGaSZy5TGQIUajQgAxobZxhKJT1OhSXIHtH94-jjKB5twK_6WxhDq6x9onXUssjMHXkLI_0QwQFGy-8vvrumapTJrtYlNCqzOFTzHwjZLt8d9HF93wTB3odhb99dVBVwszhgpYt4QzEvUDLzM8lUyBWPZeAJibGm8BMtEIOoJBRCMaYFBhRaxSrJeJsLRts6CXHcG3ATD17PgL1k1AA83C22yCuigtClrJ0s06It02aaAsP6pUa5c-UYtNUC_hXi_s3UXKGb2RNw7z7cW4SupFPZ2gPYUPkWbHdyhO3nc7JLLJnU3tJvwa1u_evuiuLhNvz8OrMVGvVsQoY1x50UmjQlQ8gXpae2CNCcdGfTb-OyJIM52lxxzsnn4aBPbFlzMjCEElJps0949QFVTgyN_5R08nLs9vp-m_TOxjYlZZtwr-DohsdT4JtuT01wEpWqwkM4vpZVfASbeZGrJ0B87qs4tvlWGgkdcM2liEQmBENry3wHWvVSpdlCON3U75ikfq2V_sfiOvC2eeOiEg25om_XrH7Tz8h924ZiepouvEfqSfS7XEsaKxYJXwslJJeIXHkiEY_iIDu17aQLH3SZLneMA6-ax-g9TEqI56qYYZ_IyO-HXhQ68LgytWYmYUitf3YgWTPCtamuP8nHZ1ahPGkj0PUjB3aNuS6n9L8_4enV838Jt_eHnwbp4ODo8BncCQytyN6C7cBmOZ2p5xgXluKF3YwETq579_8GNdR0dw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFL2CTiD2gGADFhhgJDSJh6xN7CTuYz-oBlTTNDqxt8iO7a2iS6aSPvSX8He5dj62MkC8VYlt3drXN_fEJ-cCvI8xKeZKZD7XGQKU2GpAhnFkgyFVWvVELB1B9jg-OmOfz6Pzmptjv4WpZ_DHoaVVoUUuWNvdfa1Mtz5j7GLaTWNudWdsts7692GLMcR4HdgaTE6_zdpQnFBXddW2922Hm3PKO2NsPJecfP-fcs671Mlb_C_3SJo8gcd1LkkG1eI_hXs634HdQY44-mpNDohjd7rX5jvwYNj82r4lQbgLP7-uXMlEs1qQWUM6J4UhbQ0PcqrN0lXlWZPhavl9XpZkukYnKK4EOZlNx8TVGSdTy_AglVj6QlRfNOXE8uovyCAv5_5oHPTJ6HLuzojcJXReHN0Sawrs6Y_0Ao2oZA6ewdnk42x05NfFGvwsCnnpI4zTvBfizASZ4poKLSIV9qTCFF4GiZEI7XRCpdScG4l5mtGRTjLRF5LHfZPQ59DJi1zvAQlEoKPIHYDGTJpQGKEkk5mUHMFSFnjQbZYqzWolc1tQY5EGjXj5b4vrwYe2x3Wl4vGPtkO7-m07q7_tLhTLi7TezmlPYSAURsWR5kwGRmqphEIoKRKFABEH2W98J21cOkWwShHf4n_w4F17G7ezPaMRuS5W2IZZPXzaY9SDF5WrtZZQGruA6UGy4YQbpm7eyeeXTjI8QVTOAubBgXXXG5P-Ngkv_7fhW3h4Mp6k00_HX17Bo9ASftz7qX3olMuVfo0ZWynf1PvyFxbPN0c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+Treatment+of+Pediatric+Refractory+Burkitt+Lymphoma+PTLD+after+Liver+Transplantation+using+Anti-CD19+Chimeric+Antigen+Receptor+T-Cell+Therapy&rft.jtitle=Cell+transplantation&rft.au=Wang%2C+Tianyi&rft.au=Feng%2C+Mingxuan&rft.au=Luo%2C+Chengjuan&rft.au=Wan%2C+Xinyu&rft.date=2021&rft.pub=Sage+Publications+Ltd&rft.issn=0963-6897&rft.eissn=1555-3892&rft.volume=30&rft_id=info:doi/10.1177%2F0963689721996649
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0963-6897&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0963-6897&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0963-6897&client=summon